Columnists / Reporters
The recent boom in health-care mergers and acquisitions, which resounded loudly with Monday's $160 billion Pfizer/Allergan deal, already involves a small Philadelphia generic-drug company that has spent most of its 73-year existence trying to stay under the radar.
Special Report: Forgotten gems along North Broad Street
Are you a teacher or do you know a teacher? Educators can learn about money and personal finance at the Philadelphia Federal Reserve Bank's special courses specifically aimed at helping them in the classroom.
Print Offers Online